Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest announcement is out from Rezolute ( (RZLT) ).
Rezolute, Inc. announced that the FDA has granted Breakthrough Therapy Designation to its drug, ersodetug, for treating hypoglycemia caused by congenital hyperinsulinism. This designation, based on significant data from the Phase 2b RIZE study, highlights ersodetug’s potential to substantially improve patient outcomes, reinforcing Rezolute’s position as a leader in addressing hyperinsulinism. The company is focused on completing the sunRIZE study and initiating a Phase 3 trial for tumor HI, with the FDA’s Orphan Drug Designation further supporting its innovative approach.
More about Rezolute
Rezolute, Inc. is a late-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, particularly those involving hypoglycemia due to hyperinsulinism (HI). Its primary product, ersodetug, is an antibody therapy designed to treat all forms of HI, showing significant benefits in clinical trials and real-world applications for both congenital and tumor HI.
YTD Price Performance: 1.17%
Average Trading Volume: 385,383
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $301.9M
For an in-depth examination of RZLT stock, go to TipRanks’ Stock Analysis page.
